🧬🖥️ Our latest publication reveals a shift in strategies to discover novel drug targets over the past 20 years: after 2015, biomedical evidence supporting a target-disease indication increasingly appears before the approval year www.nature.com/articles/s41...

Open Targets Platform data is now available on @amazonwebservices.bsky.social through the Open Data Program! registry.opendata.aws/opentargets/

🔬New Perturbation Catalogue update! With a redesigned interface, richer datasets and powerful analysis workflows, it’s now easier than ever to explore genetic perturbation data. www.ebi.ac.uk/perturbation... #Bioinformatics #FunctionalGenomics @training.ebi.embl.org @opentargets.org

The Perturbation Catalogue is live! 🧬🔎🖥️ It aims to bring genetic perturbation data into one curated, harmonised, and discoverable platform. Take a look! www.ebi.ac.uk/perturbation...

🧬🖥️ "This integration is a great example of bringing leading AI to platforms and data that are already widely used across the industry.” — Jonah Cool, Head of Life Sciences Partnerships, Anthropic Find out more about the Open Targets Platform MCP server: blog.opentargets.org/official-ope...

The needle in the haystack problem: spotting novel drug targets among redundant evidence. Our solution? A time-series novelty metric for Open Targets Platform associations. Thanks to Coté Falaguera & @opentargets.org partners for making this happen.

Out now in Nature Communications! 🧬🖥️ An Open Targets team developed a metric for the novelty of a target in the context of a disease, according to current available knowledge. This allows drug discovery scientists to easily identify potentially novel targets www.nature.com/articles/s41...

Out now! 🧬 Loss of CHD1 and MAP3K7 creates an acquired cancer vulnerability, highlighting these genes as potential biomarkers of immune checkpoint blockade response Find out more: www.cell.com/cell-reports...

New biomarkers for cancer immunotherapy have been identified. 🔎 Researchers found that loss of two genes, CHD1 and MAP3K7, makes tumours more likely to respond to immunotherapy. The findings could help support more personalised cancer treatment 👇 bit.ly/4sMBTq2

We're recruiting 3 roles through @sangerinstitute.bsky.social 👩‍🔬🧬💻 NEW: ➡ Postdoc with @carlanderson.bsky.social ➡ Technical Specialist with @bayraktarlab.bsky.social ALSO: ➡ (Senior) Postdoc in Mo Lotfollahi’s lab More information in the thread See all available jobs: opentargets.org/jobs

🚀 Announcing the Official @opentargets.org MCP! We've partnered with @anthropic.com to give AI seamless access to high-quality genetic and target-discovery data. Open for the entire community to accelerate therapeutic development. Read more at blog.opentargets.org/official-ope...

Introducing the official Open Targets Platform Model Context Protocol 🧬🖥️ In partnership with @anthropic.com, we’ve created an MCP server making Open Targets Platform data accessible to AI-powered tools and agents Try it out and watch out for future releases: mcp.platform.opentargets.org/mcp

The Wellcome Genome Campus lit up for the holidays ✨ 📸 Helena Cornu

NEW: NLP data scientists/scientific data engineers at @ebi.embl.org Develop a comprehensive open source side effect resource and standardised AI/ML training sets to improve early identification of safety liabilities Apply by 11 January embl.wd103.myworkdayjobs.com/en-US/EMBL/j...

Open Targets Platform 25.12 is out now! Thanks to a GWAS Catalog update including 3 major studies using UK Biobank data, we now have over 1.4 million GWAS credible sets in the Platform. Discover the data, feature, and technical updates in this release: blog.opentargets.org/open-targets... 🧬🖥️

NEW: multiple (senior) postdoctoral fellow roles in Mo Lotfollahi's group at @sangerinstitute.bsky.social There are many research focus areas available, including Open Targets translational AI projects Apply now: sanger.wd103.myworkdayjobs.com/en-US/Wellco...

#OnThisDay 10 years ago, we launched the Open Targets Platform! 🎂 🧬🖥️

NEW: Technical Specialist @sangerinstitute.bsky.social Perform large-scale phenotypic CRISPR screens on human iPSC-derived microglia to identify modifiers of immune dysfunction relating to neurodegeneration 🧬 Apply by 11 January: sanger.wd103.myworkdayjobs.com/en-US/Wellco... #ScienceJobs

#Postdoc alert! We are looking for motivated individual with experience in computational systems biology to join our NetworkCommons initiative to benchmark and democratise network contextualisation methods across multiple applications. Deadline Dec 17th link here: tinyurl.com/yrrzxa94

Can we use #AI to revolutionise drug discovery? Meet Lit-OTAR, a deep learning framework built by Europe PMC and @opentargets.org It’s identified >48.5 million unique associations, accelerating the drug discovery process! Read the thread for a paper summary👇 #AI4Science #BioNLP #DrugDiscovery

NEW: Postdoc with @epetsalaki.bsky.social @juliosaezrod.bsky.social and Tamas Korcsmáros Benchmark and integrate state-of-the-art network contextualisation methods, combining large-scale transcriptomics, proteomics, and single-cell data Apply by 17 Dec embl.wd103.myworkdayjobs.com/en-US/EMBL/j...

The recently-announced Open Psychiatry Project is the first initiative to jointly analyse UK mental health research data Findings from this project will be integrated into the Open Targets Platform to help identify and prioritise the most promising therapeutic targets.

Millions of people are affected by mental health conditions, yet progress in treatment has been slow. The Open Psychiatry Project aims to change that with a secure platform linking genetic and clinical mental health data. @cam.ac.uk @opentargets.org www.ebi.ac.uk/about/news/a...

And that's the Open Targets Hackathon done! 🧬🖥️ Thank you to everyone who joined in person and online, and who contributed to make this event a success Particular thanks to our sponsors: Gates Foundation, Google Cloud, and @thehyvenl.bsky.social 🎉

Open Targets Hackathon Day 1! Following our official kick off yesterday, there was some incredible energy and focus in the room Thanks to our sponsors Gates Foundation, Google Cloud, and @thehyvenl.bsky.social for making this possible!

The Open Targets Hackathon is today! 🎉 We're super excited to kick off this event celebrating 10 years of the Open Targets Platform Thank you to Google Cloud for sponsoring our compute and Hariprasad Radhakrishnan for mentoring our teams and sharing this video — made with Google Veo 3! 🖥️🧬

At #ASHG25 and want to find out more about the largest and most comprehensive systematic analysis of common variation in humans? Go find Daniel at poster board 1014T!

We're at #ASHG2025! Come say hello and find out more about Open Targets projects 👋

CLOSING: Postdoc in @francescoiorio.bsky.social's lab at @humantechnopole.bsky.social Apply through LinkedIn by 5 October: www.linkedin.com/jobs/view/43... #scienceJobs #AcademicSky #postdocJobs

Out now in Nature Comms: the largest trans-eQTL meta-analysis in a single cell type! An Open Targets team led by Krista Freimann and @kauralasoo.bsky.social analysed 3,734 lymphoblastoid cell line samples across nine cohorts, identifying four robust loci www.nature.com/articles/s41...

CLOSING: ➡️ Senior Bioinformatician with Roser Vento Tormo sanger.wd103.myworkdayjobs.com/en-US/Wellco... ➡️ Technical Specialist (neuro) with Omer Ali Bayraktar sanger.wd103.myworkdayjobs.com/en-US/Wellco... Both @sangerinstitute.bsky.social roles close on 2 October

Excited for a major milestone in our efforts to map enhancers and interpret variants in the human genome: The E2G Portal! e2g.stanford.edu This collates our predictions of enhancer-gene regulatory interactions across >1,600 cell types and tissues. Uses cases 👇 1/

The Open Targets Platform autumn release is out! 🍂 We have ingested the full dataset of over 13 million enhancer-gene regulatory interactions in the human genome across 1,458 DNase-seq experiments covering 369 cell types and tissues from the ENCODE-rE2G model blog.opentargets.org/open-targets...

🚩1 MILLION curated associations!!! 🚩 Launched in 2008, took us 15 years to reach 500K, and thanks to your research and collaboration, we doubled the number in less than 3 years! See some data insights tinyurl.com/mw53njbb #OpenAccess

Last call to submit a project for the Open Targets Hackathon! Submit a project by 12 September: docs.google.com/forms/d/e/1F... We will prioritise projects where the project leads have signed up to attend the hackathon. Registrations are currently full but you can sign up to the waiting list

Out now on bioRxiv! 🧬🖥️ A team from the Cowley, Bassett, and @gosiatrynka.bsky.social labs integrate pooled iPSC phenotyping, transcriptomics, and CRISPR perturbations to identify genetic drivers of molecular and cellular phenotypes in microglia www.biorxiv.org/content/10.1... #neuroskyence

Out now! 🧬 Lewis Evans and the team at @sangerinstitute.bsky.social and UCL define the pathways for tau entry into human neurons, a key mechanism for the progression of tauopathies associated with Parkinson’s and Alzheimer’s disease www.embopress.org/doi/full/10.... #neuroscience #neuroskyence

CLOSING: Front end developer for the Open Targets Platform Join @carcruz.dev's team and help us turn complex data into powerful discovery tools, working closely with our industry and academic partners Apply by 19 August embl.wd103.myworkdayjobs.com/EMBL/job/Hin... #ReactJobs #DevJobs

NEW: Front-End Web Dev @ebi.embl.org Join the Open Targets Platform team! Design and build this cloud-first, open-source application, used to explore and prioritise potential drug targets embl.wd103.myworkdayjobs.com/EMBL/job/Hin...

“It’s been a very collaborative experience.” @malloryfreeberg.bsky.social talks to us about developing the Perturbation Catalogue The beta version is available to explore now, and the team are keen to hear your feedback! www.ebi.ac.uk/perturbation... blog.opentargets.org/creating-a-p...

Google Cloud is sponsoring the compute for the Open Targets hackathon! There is now a waiting list to attend the event in person, but project submissions and online registrations are still open. The two-day hackathon will explore data, analyses, and tools for target discovery

Meet Carlos Cruz! Carlos joined the Open Targets Platform team in 2021 🖥️🧬 @carcruz.dev, what is your role in Open Targets?

We're proud to play our part in diversifying genetic and genomic datasets by supporting this important work in Latin America co-led by Open Targets Science Director @gosiatrynka.bsky.social Greater genetic diversity improves discovery and brings us closer to better, more inclusive medicines

🧬 New @emblebi.bsky.social service beta launched: Perturbation Catalogue 🔎 Browse genetic perturbation datasets 🧠 Train models 🧬 Interpret variant function 🧭 Explore gene dependencies Search, test APIs, suggest datasets, send feedback! 🔗 www.ebi.ac.uk/perturbation... Funded by @opentargets.org

We have now deprecated Open Targets Genetics — it has been superseded by the Open Targets Platform The team said goodbye to Open Targets Genetics, through the medium of memes Enjoy!

Open licenses power discovery! Melissa Harrison shares a @opentargets.org use case: Open Targets identifies and prioritises drug targets using AI to extract gene, drug, and disease mentions and relationships to building drug development evidence #ChooseOpenWebinar for updates 💡 #MedLib #PhDsky

Open Targets Genetics has now been deprecated It has been superseded by the Open Targets Platform

Delighted to share the first preprint of my postdoc in the @carlanderson.bsky.social lab www.medrxiv.org/content/10.1...! 🚨 A super exciting study I co-led with the very talented @tobioinformatics.bsky.social . Stay tuned to see what we learned about genetic susceptibility to complex disease. 🧬🧵 1/

🚨New preprint just dropped 🚨 medrxiv.org/content/10.1101/2025.06.24.25330216 The main output from my PhD is finally public and we’re SUPER excited about the findings! If you’re interested in what we learnt about IBD with a massive 700+ sample sc-eQTL dataset of the gut, read on!

🧬 The latest Open Targets Platform release includes the first genetic evidence for ESR1 in osteoporosis ESR1 is a known target for osteoporosis, with approved drugs such as Estradiol, but this is the first time we have genetic evidence for this association platform.opentargets.org/disease/EFO_...